The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.
 
Stephen V. Liu
Consulting or Advisory Role - Apollomics; ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Genentech; Guardant Health; HERON; Ignyta; Inivata; Janssen Oncology; Lilly; Loxo; Merck; MSD Oncology; Pfizer; PharmaMar; Regeneron; Roche; Taiho Pharmaceutical; Takeda; Tempus
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Esanex (Inst); Genentech/Roche (Inst); Ignyta (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Molecular Partners (Inst); OncoMed (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Threshold Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech
 
Richard Delmar Hall
Consulting or Advisory Role - AstraZeneca/MedImmune; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst)
 
Andreas Nicholas Saltos
Research Funding - Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Gregory Alan Otterson
Consulting or Advisory Role - Novartis; Novocure; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Ming Tony Tan
No Relationships to Disclose
 
Sacha Gnjatic
No Relationships to Disclose
 
Ryan D. Gentzler
Honoraria - Rockpointe CME; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Helsinn Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst)
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Elad Sharon
No Relationships to Disclose